Bris­tol-My­ers, Ab­b­Vie's mul­ti­ple myelo­ma drug wins sec­ond EU nod as part of triple reg­i­men

Less than a year af­ter the FDA cleared Bris­tol-My­ers Squibb $BMY and Ab­b­Vie’s $AB­BV ap­proved Em­plic­i­ti in­jec­tion for in­tra­venous use in com­bi­na­tion with Cel­gene’s …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.